Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Jim Cramer evaluates if the Las Vegas Sphere is worth a buy
Jim Cramer at the NYSE with Mad Money graphic, June 30, 2022. Virginia Sherwood | CNBC CNBC’s Jim Cramer has his eye on Sphere Entertainment, the company that owns the 580,000 square foot Sphere that looms in the Las Vegas skyline, but he is not recommending it to investors. “The stock’s certainly been a solid…
Jim Cramer sees FTC Chair Lina Khan’s policies hurting investor portfolios
CNBC’s Jim Cramer said Federal Trade Commission chair Lina Khan’s attempts to stop mergers and acquisitions from going through is hurting stock portfolios in the process. “Khan’s FTC has deterred many a potential merger, and that’s kept stock valuations much lower than they should be, as the Nippon Steel-U.S. Steel deal shows,” Cramer said Monday….
Did you know Alcoa helped make all this?
Alcoa is an integral part of consumers’ lives whether they know it or not.
Suze’s top 5 ‘forever nevers’
Suze Orman counts down the five money mistakes you should never make.
What Oprah knows for sure
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email In the series finale, Oprah Winfrey tells Suze she knew from the very first time she was on her show, that Suze was destined to do something special. 03:04 Sat, Mar 28 20159:05 PM EDT
Circuit breakers suspended in China
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Eunice Yoon reports Chinese regulators have suspended market circuit breakers, according to the Shanghai Stock Exchange. 01:45 Thu, Jan 7 20169:43 AM EST
